BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bartlett JB, Michael A, Clarke IA, Dredge K, Nicholson S, Kristeleit H, Polychronis A, Pandha H, Muller GW, Stirling DI. Phase I study to determine the safety, tolerability and immunostimulatory activity of thalidomide analogue CC-5013 in patients with metastatic malignant melanoma and other advanced cancers. Br J Cancer. 2004;90:955-961. [PMID: 14997189 DOI: 10.1038/sj.bjc.6601579] [Cited by in Crossref: 113] [Cited by in F6Publishing: 105] [Article Influence: 6.3] [Reference Citation Analysis]
Number Citing Articles
1 Lorigan P, Eisen T, Hauschild A. Systemic therapy for metastatic malignant melanoma - from deeply disappointing to bright future? Experimental Dermatology 2008;17:383-94. [DOI: 10.1111/j.1600-0625.2007.00673.x] [Cited by in Crossref: 43] [Cited by in F6Publishing: 36] [Article Influence: 3.1] [Reference Citation Analysis]
2 Bartlett JB, Tozer A, Stirling D, Zeldis JB. Recent clinical studies of the immunomodulatory drug (IMiD) lenalidomide. Br J Cancer 2005;93:613-9. [PMID: 16222306 DOI: 10.1038/sj.bjc.6602774] [Cited by in Crossref: 51] [Cited by in F6Publishing: 38] [Article Influence: 3.0] [Reference Citation Analysis]
3 Marinaccio C, Nico B, Maiorano E, Specchia G, Ribatti D. Insights in Hodgkin Lymphoma angiogenesis. Leukemia Research 2014;38:857-61. [DOI: 10.1016/j.leukres.2014.05.023] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 3.4] [Reference Citation Analysis]
4 Liu WM, Nizar S, Dalgleish AG. Gemcitabine and lenalidomide combination in a patient with metastatic pancreatic cancer: a case study. Med Oncol 2010;27:430-3. [DOI: 10.1007/s12032-009-9228-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
5 Thotathil Z, Jameson MB. Early experience with novel immunomodulators for cancer treatment. Expert Opin Investig Drugs 2007;16:1391-403. [PMID: 17714025 DOI: 10.1517/13543784.16.9.1391] [Cited by in Crossref: 19] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
6 Markovic SN, Erickson LA, Rao RD, Weenig RH, Pockaj BA, Bardia A, Vachon CM, Schild SE, McWilliams RR, Hand JL, Laman SD, Kottschade LA, Maples WJ, Pittelkow MR, Pulido JS, Cameron JD, Creagan ET; Melanoma Study Group of Mayo Clinic Cancer Center. Malignant melanoma in the 21st century, part 2: staging, prognosis, and treatment. Mayo Clin Proc 2007;82:490-513. [PMID: 17418079 DOI: 10.4065/82.4.490] [Cited by in Crossref: 101] [Cited by in F6Publishing: 81] [Article Influence: 6.7] [Reference Citation Analysis]
7 Maier SK, Hammond JM. Role of Lenalidomide in the Treatment of Multiple Myeloma and Myelodysplasic Syndrome. Ann Pharmacother 2006;40:286-9. [DOI: 10.1345/aph.1g170] [Cited by in Crossref: 12] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
8 Vijay A, Gertz MA. Current Treatment Options for Waldenström Macroglobulinemia. Clinical Lymphoma and Myeloma 2008;8:219-29. [DOI: 10.3816/clm.2008.n.029] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
9 Dasanu CA. Immune alterations in untreated and treated multiple myeloma. J Oncol Pharm Pract 2012;18:257-63. [PMID: 21859744 DOI: 10.1177/1078155211412842] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
10 Elice F, Rodeghiero F. Hematologic malignancies and thrombosis. Thromb Res 2012;129:360-6. [PMID: 22197450 DOI: 10.1016/j.thromres.2011.11.034] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 2.8] [Reference Citation Analysis]
11 Dalgleish AG. Vaccines versus immunotherapy: overview of approaches in deciding between options. Hum Vaccin Immunother 2014;10:3369-74. [PMID: 25625932 DOI: 10.4161/21645515.2014.980707] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
12 Ji Z, Flaherty KT, Tsao H. Molecular therapeutic approaches to melanoma. Molecular Aspects of Medicine 2010;31:194-204. [DOI: 10.1016/j.mam.2010.02.004] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
13 Fehniger TA, Uy GL, Trinkaus K, Nelson AD, Demland J, Abboud CN, Cashen AF, Stockerl-Goldstein KE, Westervelt P, DiPersio JF, Vij R. A phase 2 study of high-dose lenalidomide as initial therapy for older patients with acute myeloid leukemia. Blood 2011;117:1828-33. [PMID: 21051557 DOI: 10.1182/blood-2010-07-297143] [Cited by in Crossref: 80] [Cited by in F6Publishing: 80] [Article Influence: 6.7] [Reference Citation Analysis]
14 Gullestad L, Ueland T, Fjeld JG, Holt E, Gundersen T, Breivik K, Følling M, Hodt A, Skårdal R, Kjekshus J, Andreassen A, Kjekshus E, Wergeland R, Yndestad A, Frøland SS, Semb AG, Aukrust P. Effect of thalidomide on cardiac remodeling in chronic heart failure: results of a double-blind, placebo-controlled study. Circulation 2005;112:3408-14. [PMID: 16301340 DOI: 10.1161/CIRCULATIONAHA.105.564971] [Cited by in Crossref: 58] [Cited by in F6Publishing: 21] [Article Influence: 3.4] [Reference Citation Analysis]
15 Petrylak DP, Vogelzang NJ, Budnik N, Wiechno PJ, Sternberg CN, Doner K, Bellmunt J, Burke JM, de Olza MO, Choudhury A, Gschwend JE, Kopyltsov E, Flechon A, Van As N, Houede N, Barton D, Fandi A, Jungnelius U, Li S, de Wit R, Fizazi K. Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol 2015;16:417-25. [PMID: 25743937 DOI: 10.1016/S1470-2045(15)70025-2] [Cited by in Crossref: 104] [Cited by in F6Publishing: 43] [Article Influence: 14.9] [Reference Citation Analysis]
16 Xu Y, Sun J, Sheard MA, Tran HC, Wan Z, Liu WY, Asgharzadeh S, Sposto R, Wu HW, Seeger RC. Lenalidomide overcomes suppression of human natural killer cell anti-tumor functions by neuroblastoma microenvironment-associated IL-6 and TGFβ1. Cancer Immunol Immunother 2013;62:1637-48. [PMID: 23982484 DOI: 10.1007/s00262-013-1466-y] [Cited by in Crossref: 47] [Cited by in F6Publishing: 41] [Article Influence: 5.2] [Reference Citation Analysis]
17 Gamerith G, Auer T, Amann A, Putzer D, Schenk B, Kircher B, Hilbe W, Zwierzina H, Loeffler-Ragg J. Increase in antibody-dependent cellular cytotoxicity (ADCC) in a patient with advanced colorectal carcinoma carrying a KRAS mutation under lenalidomide therapy. Cancer Biol Ther 2014;15:266-70. [PMID: 24351336 DOI: 10.4161/cbt.27327] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
18 Dalgleish AG, Stern PL. The failure of radical treatments to cure cancer: can less deliver more? Ther Adv Vaccines Immunother 2018;6:69-76. [PMID: 30623172 DOI: 10.1177/2515135518815393] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
19 Zhu D, Corral LG, Fleming YW, Stein B. Immunomodulatory drugs Revlimid (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation. Cancer Immunol Immunother 2008;57:1849-59. [PMID: 18392823 DOI: 10.1007/s00262-008-0512-7] [Cited by in Crossref: 118] [Cited by in F6Publishing: 113] [Article Influence: 8.4] [Reference Citation Analysis]
20 Lam JS, Shvarts O, Leppert JT, Figlin RA, Belldegrun AS. Renal cell carcinoma 2005: new frontiers in staging, prognostication and targeted molecular therapy. J Urol. 2005;173:1853-1862. [PMID: 15879764 DOI: 10.1097/01.ju.0000165693.68449.c3] [Cited by in Crossref: 242] [Cited by in F6Publishing: 219] [Article Influence: 14.2] [Reference Citation Analysis]
21 Ramchandren R. Advances in the treatment of relapsed or refractory Hodgkin's lymphoma. Oncologist 2012;17:367-76. [PMID: 22387318 DOI: 10.1634/theoncologist.2011-0258] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
22 Mentlik James A, Cohen AD, Campbell KS. Combination immune therapies to enhance anti-tumor responses by NK cells. Front Immunol 2013;4:481. [PMID: 24391651 DOI: 10.3389/fimmu.2013.00481] [Cited by in Crossref: 45] [Cited by in F6Publishing: 49] [Article Influence: 5.0] [Reference Citation Analysis]
23 Kasper B, D'Hondt V, Vereecken P, Awada A. Novel treatment strategies for malignant melanoma: a new beginning? Crit Rev Oncol Hematol 2007;62:16-22. [PMID: 17208006 DOI: 10.1016/j.critrevonc.2006.11.007] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 1.5] [Reference Citation Analysis]
24 Becker JC, Kirkwood JM, Agarwala SS, Dummer R, Schrama D, Hauschild A. Molecularly targeted therapy for melanoma: Current reality and future options. Cancer 2006;107:2317-27. [DOI: 10.1002/cncr.22273] [Cited by in Crossref: 39] [Cited by in F6Publishing: 29] [Article Influence: 2.4] [Reference Citation Analysis]
25 Haddad TC, Greeno EW. Chemotherapy-induced thrombosis. Thrombosis Research 2006;118:555-68. [DOI: 10.1016/j.thromres.2005.10.015] [Cited by in Crossref: 205] [Cited by in F6Publishing: 171] [Article Influence: 12.8] [Reference Citation Analysis]
26 Gandhi AK, Shi T, Li M, Jungnelius U, Romano A, Tabernero J, Siena S, Schafer PH, Chopra R. Immunomodulatory effects in a phase II study of lenalidomide combined with cetuximab in refractory KRAS-mutant metastatic colorectal cancer patients. PLoS One 2013;8:e80437. [PMID: 24244687 DOI: 10.1371/journal.pone.0080437] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 2.4] [Reference Citation Analysis]
27 Drappatz J, Wong ET, Schiff D, Kesari S, Batchelor TT, Doherty L, Lafrankie DC, Ramakrishna N, Weiss S, Smith ST, Ciampa A, Zimmerman J, Ostrowsky L, David K, Norden A, Barron L, Sceppa C, Black PM, Wen PY. A Pilot Safety Study of Lenalidomide and Radiotherapy for Patients With Newly Diagnosed Glioblastoma Multiforme. International Journal of Radiation Oncology*Biology*Physics 2009;73:222-7. [DOI: 10.1016/j.ijrobp.2008.03.046] [Cited by in Crossref: 44] [Cited by in F6Publishing: 35] [Article Influence: 3.4] [Reference Citation Analysis]
28 Ashrani AA, Rajkumar SV. Chemotherapy-Associated Thrombosis. In: Kwaan HC, Green D, editors. Coagulation in Cancer. Boston: Springer US; 2009. pp. 181-206. [DOI: 10.1007/978-0-387-79962-9_11] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
29 Hwu WJ, Knight RD, Patnana M, Bassett R, Papadopoulos NE, Kim KB, Hwu P, Bedikian A. Phase I safety study of lenalidomide and dacarbazine in patients with metastatic melanoma previously untreated with systemic chemotherapy. Melanoma Res 2010;20:501-6. [PMID: 20859231 DOI: 10.1097/CMR.0b013e32833faf18] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
30 de Castro G, Awada A. Side effects of anti-cancer molecular-targeted therapies (not monoclonal antibodies). Current Opinion in Oncology 2006;18:307-15. [DOI: 10.1097/01.cco.0000228733.55132.ea] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
31 Pallotti MC, Nannini M, Agostinelli C, Leoni S, Scioscio VD, Mandrioli A, Lolli C, Saponara M, Pileri S, Bolondi L, Biasco G, Pantaleo MA. Long-term durable response to lenalidomide in a patient with hepatic epithelioid hemangioendothelioma. World J Gastroenterol 2014; 20(22): 7049-7054 [PMID: 24944501 DOI: 10.3748/wjg.v20.i22.7049] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
32 Dahut WL, Aragon-Ching JB, Woo S, Tohnya TM, Gulley JL, Arlen PM, Wright JJ, Ventiz J, Figg WD. Phase I study of oral lenalidomide in patients with refractory metastatic cancer. J Clin Pharmacol 2009;49:650-60. [PMID: 19451403 DOI: 10.1177/0091270009335001] [Cited by in Crossref: 43] [Cited by in F6Publishing: 40] [Article Influence: 3.3] [Reference Citation Analysis]
33 Zabransky DJ, Smith HA, Thoburn CJ, Zahurak M, Keizman D, Carducci M, Eisenberger MA, McNeel DG, Drake CG, Antonarakis ES. Lenalidomide modulates IL-8 and anti-prostate antibody levels in men with biochemically recurrent prostate cancer. Prostate 2012;72:487-98. [PMID: 21748755 DOI: 10.1002/pros.21449] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
34 Galustian C, Meyer B, Labarthe MC, Dredge K, Klaschka D, Henry J, Todryk S, Chen R, Muller G, Stirling D, Schafer P, Bartlett JB, Dalgleish AG. The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells. Cancer Immunol Immunother 2009;58:1033-45. [PMID: 19009291 DOI: 10.1007/s00262-008-0620-4] [Cited by in Crossref: 271] [Cited by in F6Publishing: 253] [Article Influence: 19.4] [Reference Citation Analysis]
35 Idler I, Bhattacharya N, Döhner H, Stilgenbauer S, Mertens D. Immune modulatory agents in hematopoietic malignancies. Cancer Treatment Reviews 2011;37:S2-7. [DOI: 10.1016/j.ctrv.2011.05.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
36 Pourcher V, Desnoyer A, Assoumou L, Lebbe C, Curjol A, Marcelin AG, Cardon F, Gibowski S, Salmon D, Chennebault JM, Poizot-Martin I, Peytavin G, Boué F, Costagliola D. Phase II Trial of Lenalidomide in HIV-Infected Patients with Previously Treated Kaposi's Sarcoma: Results of the ANRS 154 Lenakap Trial. AIDS Res Hum Retroviruses 2017;33:1-10. [PMID: 27405442 DOI: 10.1089/AID.2016.0069] [Cited by in Crossref: 24] [Cited by in F6Publishing: 15] [Article Influence: 4.8] [Reference Citation Analysis]
37 Crane E, List A. Immunomodulatory drugs. Cancer Invest 2005;23:625-34. [PMID: 16305990 DOI: 10.1080/07357900500283101] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 1.8] [Reference Citation Analysis]
38 Crane E, List A. Lenalidomide: an immunomodulatory drug. Future Oncol 2005;1:575-83. [PMID: 16556034 DOI: 10.2217/14796694.1.5.575] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 1.3] [Reference Citation Analysis]
39 Warren KE, Goldman S, Pollack IF, Fangusaro J, Schaiquevich P, Stewart CF, Wallace D, Blaney SM, Packer R, Macdonald T, Jakacki R, Boyett JM, Kun LE. Phase I trial of lenalidomide in pediatric patients with recurrent, refractory, or progressive primary CNS tumors: Pediatric Brain Tumor Consortium study PBTC-018. J Clin Oncol 2011;29:324-9. [PMID: 21149652 DOI: 10.1200/JCO.2010.31.3601] [Cited by in Crossref: 62] [Cited by in F6Publishing: 32] [Article Influence: 5.2] [Reference Citation Analysis]
40 Finlay JL, Zacharoulis S. The treatment of high grade gliomas and diffuse intrinsic pontine tumors of childhood and adolescence: a historical - and futuristic - perspective. J Neurooncol 2005;75:253-66. [PMID: 16195805 DOI: 10.1007/s11060-005-6747-7] [Cited by in Crossref: 66] [Cited by in F6Publishing: 47] [Article Influence: 4.1] [Reference Citation Analysis]
41 Eve HE, Carey S, Richardson SJ, Heise CC, Mamidipudi V, Shi T, Radford JA, Auer RL, Bullard SH, Rule SA. Single-agent lenalidomide in relapsed/refractory mantle cell lymphoma: results from a UK phase II study suggest activity and possible gender differences. Br J Haematol 2012;159:154-63. [PMID: 22881386 DOI: 10.1111/bjh.12008] [Cited by in Crossref: 65] [Cited by in F6Publishing: 65] [Article Influence: 6.5] [Reference Citation Analysis]
42 Berg SL, Cairo MS, Russell H, Ayello J, Ingle AM, Lau H, Chen N, Adamson PC, Blaney SM. Safety, pharmacokinetics, and immunomodulatory effects of lenalidomide in children and adolescents with relapsed/refractory solid tumors or myelodysplastic syndrome: a Children's Oncology Group Phase I Consortium report. J Clin Oncol 2011;29:316-23. [PMID: 21149673 DOI: 10.1200/JCO.2010.30.8387] [Cited by in Crossref: 43] [Cited by in F6Publishing: 27] [Article Influence: 3.6] [Reference Citation Analysis]
43 Carballido E, Veliz M, Komrokji R, Pinilla-Ibarz J. Immunomodulatory drugs and active immunotherapy for chronic lymphocytic leukemia. Cancer Control 2012;19:54-67. [PMID: 22143062 DOI: 10.1177/107327481201900106] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
44 Lam JS, Leppert JT, Belldegrun AS, Figlin RA. Novel approaches in the therapy of metastatic renal cell carcinoma. World J Urol 2005;23:202-12. [PMID: 15812574 DOI: 10.1007/s00345-004-0466-0] [Cited by in Crossref: 159] [Cited by in F6Publishing: 139] [Article Influence: 9.4] [Reference Citation Analysis]
45 Emole JN, Locke FL, Pinilla-Ibarz J. An update on current and prospective immunotherapies for chronic lymphocytic leukemia. Immunotherapy 2015;7:455-66. [PMID: 25917633 DOI: 10.2217/imt.15.14] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
46 Vallet S, Witzens-Harig M, Jaeger D, Podar K. Update on immunomodulatory drugs (IMiDs) in hematologic and solid malignancies. Expert Opin Pharmacother 2012;13:473-94. [PMID: 22324734 DOI: 10.1517/14656566.2012.656091] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
47 Richardson PG, Mitsiades C, Hideshima T, Anderson KC. Lenalidomide in multiple myeloma. Expert Rev Anticancer Ther 2006;6:1165-73. [PMID: 16925483 DOI: 10.1586/14737140.6.8.1165] [Cited by in Crossref: 42] [Cited by in F6Publishing: 33] [Article Influence: 2.6] [Reference Citation Analysis]
48 Sumrall A, Fredericks R, Berthold A, Shumaker G. Lenalidomide stops progression of multifocal epithelioid hemangioendothelioma including intracranial disease. J Neurooncol. 2010;97:275-277. [PMID: 19898746 DOI: 10.1007/s11060-009-0017-z] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 1.6] [Reference Citation Analysis]
49 Mouawad R, Sebert M, Michels J, Bloch J, Spano J, Khayat D. Treatment for metastatic malignant melanoma: Old drugs and new strategies. Critical Reviews in Oncology/Hematology 2010;74:27-39. [DOI: 10.1016/j.critrevonc.2009.08.005] [Cited by in Crossref: 78] [Cited by in F6Publishing: 76] [Article Influence: 6.5] [Reference Citation Analysis]
50 Tefferi A, Cortes J, Verstovsek S, Mesa RA, Thomas D, Lasho TL, Hogan WJ, Litzow MR, Allred JB, Jones D, Byrne C, Zeldis JB, Ketterling RP, Mcclure RF, Giles F, Kantarjian HM. Lenalidomide therapy in myelofibrosis with myeloid metaplasia. Blood 2006;108:1158-64. [DOI: 10.1182/blood-2006-02-004572] [Cited by in Crossref: 179] [Cited by in F6Publishing: 151] [Article Influence: 11.2] [Reference Citation Analysis]
51 Pratt G, Goodyear O, Moss P. Immunodeficiency and immunotherapy in multiple myeloma. Br J Haematol 2007;138:563-79. [PMID: 17686051 DOI: 10.1111/j.1365-2141.2007.06705.x] [Cited by in Crossref: 206] [Cited by in F6Publishing: 195] [Article Influence: 13.7] [Reference Citation Analysis]
52 Wu L, Parton A, Lu L, Adams M, Schafer P, Bartlett JB. Lenalidomide enhances antibody-dependent cellular cytotoxicity of solid tumor cells in vitro: influence of host immune and tumor markers. Cancer Immunol Immunother 2011;60:61-73. [PMID: 20848094 DOI: 10.1007/s00262-010-0919-9] [Cited by in Crossref: 49] [Cited by in F6Publishing: 46] [Article Influence: 4.1] [Reference Citation Analysis]
53 Le Roy A, Prébet T, Castellano R, Goubard A, Riccardi F, Fauriat C, Granjeaud S, Benyamine A, Castanier C, Orlanducci F, Ben Amara A, Pont F, Fournié JJ, Collette Y, Mege JL, Vey N, Olive D. Immunomodulatory Drugs Exert Anti-Leukemia Effects in Acute Myeloid Leukemia by Direct and Immunostimulatory Activities. Front Immunol 2018;9:977. [PMID: 29780393 DOI: 10.3389/fimmu.2018.00977] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
54 Zangari M, Elice F, Fink L, Tricot G. Thrombosis in multiple myeloma. Expert Review of Anticancer Therapy 2014;7:307-15. [DOI: 10.1586/14737140.7.3.307] [Cited by in Crossref: 47] [Cited by in F6Publishing: 37] [Article Influence: 5.9] [Reference Citation Analysis]
55 Payvandi F, Wu L, Haley M, Schafer PH, Zhang L, Chen RS, Muller GW, Stirling DI. Immunomodulatory drugs inhibit expression of cyclooxygenase-2 from TNF-α, IL-1β, and LPS-stimulated human PBMC in a partially IL-10-dependent manner. Cellular Immunology 2004;230:81-8. [DOI: 10.1016/j.cellimm.2004.09.003] [Cited by in Crossref: 58] [Cited by in F6Publishing: 49] [Article Influence: 3.2] [Reference Citation Analysis]
56 Strother JM, Beer TM, Dreicer R. Novel cytotoxic and biological agents for prostate cancer: Where will the money be in 2005? European Journal of Cancer 2005;41:954-64. [DOI: 10.1016/j.ejca.2005.02.002] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
57 Kuohung V, Goldberg LJ, Demierre M. Lenalidomide-induced purpuric eruption: A new adverse cutaneous reaction. Journal of the American Academy of Dermatology 2011;65:654-6. [DOI: 10.1016/j.jaad.2010.04.034] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
58 Ullenhag GJ, Rossmann E, Liljefors M. A phase I dose-escalation study of lenalidomide in combination with gemcitabine in patients with advanced pancreatic cancer. PLoS One 2015;10:e0121197. [PMID: 25837499 DOI: 10.1371/journal.pone.0121197] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
59 Sleijfer S, Kruit WH, Stoter G. Thalidomide in solid tumours: the resurrection of an old drug. Eur J Cancer 2004;40:2377-82. [PMID: 15519508 DOI: 10.1016/j.ejca.2004.07.023] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 1.9] [Reference Citation Analysis]
60 Rajpal R, Dowling P, Meiller J, Clarke C, Murphy WG, O'Connor R, Kell M, Mitsiades C, Richardson P, Anderson KC, Clynes M, O'Gorman P. A novel panel of protein biomarkers for predicting response to thalidomide-based therapy in newly diagnosed multiple myeloma patients. Proteomics 2011;11:1391-402. [PMID: 21365752 DOI: 10.1002/pmic.201000471] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 2.1] [Reference Citation Analysis]
61 Skolarikos AA, Papatsoris AG, Alivizatos G, Deliveliotis C. Molecular pathogenetics of renal cancer. Am J Nephrol 2006;26:218-31. [PMID: 16733347 DOI: 10.1159/000093631] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
62 Zangari M, Elice F, Tricot G. Immunomodulatory drugs in multiple myeloma. Expert Opinion on Investigational Drugs 2005;14:1411-8. [DOI: 10.1517/13543784.14.11.1411] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
63 Seeger RC. Immunology and immunotherapy of neuroblastoma. Semin Cancer Biol 2011;21:229-37. [PMID: 21971567 DOI: 10.1016/j.semcancer.2011.09.012] [Cited by in Crossref: 52] [Cited by in F6Publishing: 47] [Article Influence: 4.7] [Reference Citation Analysis]
64 Chanan-Khan A, Miller KC, Musial L, Lawrence D, Padmanabhan S, Takeshita K, Porter CW, Goodrich DW, Bernstein ZP, Wallace P. Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. J Clin Oncol. 2006;24:5343-5349. [PMID: 17088571 DOI: 10.1200/jco.2005.05.0401] [Cited by in Crossref: 315] [Cited by in F6Publishing: 127] [Article Influence: 19.7] [Reference Citation Analysis]
65 Markovic SN, Suman VJ, Rao RA, Ingle JN, Kaur JS, Erickson LA, Pitot HC, Croghan GA, McWilliams RR, Merchan J, Kottschade LA, Nevala WK, Uhl CB, Allred J, Creagan ET. A phase II study of ABT-510 (thrombospondin-1 analog) for the treatment of metastatic melanoma. Am J Clin Oncol 2007;30:303-9. [PMID: 17551310 DOI: 10.1097/01.coc.0000256104.80089.35] [Cited by in Crossref: 66] [Cited by in F6Publishing: 67] [Article Influence: 4.4] [Reference Citation Analysis]
66 Ko JM, Fisher DE. A new era: melanoma genetics and therapeutics. J Pathol 2011;223:241-50. [PMID: 21125678 DOI: 10.1002/path.2804] [Cited by in Crossref: 65] [Cited by in F6Publishing: 72] [Article Influence: 5.4] [Reference Citation Analysis]
67 Bartlett JB, Dredge K, Dalgleish AG. The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer. 2004;4:314-322. [PMID: 15057291 DOI: 10.1038/nrc1323] [Cited by in Crossref: 550] [Cited by in F6Publishing: 481] [Article Influence: 30.6] [Reference Citation Analysis]
68 Subbian S, Tsenova L, O'Brien P, Yang G, Koo MS, Peixoto B, Fallows D, Dartois V, Muller G, Kaplan G. Phosphodiesterase-4 inhibition alters gene expression and improves isoniazid-mediated clearance of Mycobacterium tuberculosis in rabbit lungs. PLoS Pathog 2011;7:e1002262. [PMID: 21949656 DOI: 10.1371/journal.ppat.1002262] [Cited by in Crossref: 66] [Cited by in F6Publishing: 64] [Article Influence: 6.0] [Reference Citation Analysis]
69 Ferrajoli A, Lee BN, Schlette EJ, O’Brien SM, Gao H, Wen S, Wierda WG, Estrov Z, Faderl S, Cohen EN. Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood. 2008;111:5291-5297. [PMID: 18334676 DOI: 10.1182/blood-2007-12-130120] [Cited by in Crossref: 308] [Cited by in F6Publishing: 294] [Article Influence: 22.0] [Reference Citation Analysis]
70 Chretien AS, Le Roy A, Vey N, Prebet T, Blaise D, Fauriat C, Olive D. Cancer-Induced Alterations of NK-Mediated Target Recognition: Current and Investigational Pharmacological Strategies Aiming at Restoring NK-Mediated Anti-Tumor Activity. Front Immunol 2014;5:122. [PMID: 24715892 DOI: 10.3389/fimmu.2014.00122] [Cited by in Crossref: 59] [Cited by in F6Publishing: 60] [Article Influence: 7.4] [Reference Citation Analysis]
71 Dietrich S, Kasper B. Targeted therapeutic strategies in malignant melanoma. Drug Discovery Today: Disease Mechanisms 2008;5:e63-8. [DOI: 10.1016/j.ddmec.2008.04.008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
72 Davies F, Baz R. Lenalidomide mode of action: linking bench and clinical findings. Blood Reviews 2010;24:S13-9. [DOI: 10.1016/s0268-960x(10)70004-7] [Cited by in Crossref: 74] [Cited by in F6Publishing: 36] [Article Influence: 6.2] [Reference Citation Analysis]
73 Lapalombella R, Andritsos L, Liu Q, May SE, Browning R, Pham LV, Blum KA, Blum W, Ramanunni A, Raymond CA, Smith LL, Lehman A, Mo X, Jarjoura D, Chen CS, Ford R Jr, Rader C, Muthusamy N, Johnson AJ, Byrd JC. Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway. Blood 2010;115:2619-29. [PMID: 19965642 DOI: 10.1182/blood-2009-09-242438] [Cited by in Crossref: 96] [Cited by in F6Publishing: 93] [Article Influence: 7.4] [Reference Citation Analysis]
74 Siegel MJ, Finlay JL, Zacharoulis S. State of the art chemotherapeutic management of pediatric brain tumors. Expert Rev Neurother 2006;6:765-79. [PMID: 16734524 DOI: 10.1586/14737175.6.5.765] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
75 Sanborn SL, Gibbons J, Krishnamurthi S, Brell JM, Dowlati A, Bokar JA, Nock C, Horvath N, Bako J, Remick SC, Cooney MM. Phase I trial of docetaxel given every 3 weeks and daily lenalidomide in patients with advanced solid tumors. Invest New Drugs 2009;27:453-60. [DOI: 10.1007/s10637-008-9200-x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.4] [Reference Citation Analysis]
76 Paoletti X, Geoerger B, Doz F, Baruchel A, Lokiec F, Le Tourneau C. A comparative analysis of paediatric dose-finding trials of molecularly targeted agent with adults’ trials. European Journal of Cancer 2013;49:2392-402. [DOI: 10.1016/j.ejca.2013.02.028] [Cited by in Crossref: 42] [Cited by in F6Publishing: 30] [Article Influence: 4.7] [Reference Citation Analysis]
77 Galustian C, Dalgleish A. Lenalidomide: a novel anticancer drug with multiple modalities. Expert Opinion on Pharmacotherapy 2008;10:125-33. [DOI: 10.1517/14656560802627903] [Cited by in Crossref: 50] [Cited by in F6Publishing: 38] [Article Influence: 3.6] [Reference Citation Analysis]
78 Dalgleish AG. Therapeutic cancer vaccines: why so few randomised phase III studies reflect the initial optimism of phase II studies. Vaccine 2011;29:8501-5. [PMID: 21933695 DOI: 10.1016/j.vaccine.2011.09.012] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
79 Dreicer R. Lenalidomide: Immunomodulatory, antiangiogenic, and clinical activity in solid tumors. Curr Oncol Rep 2007;9:120-3. [DOI: 10.1007/s11912-007-0008-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
80 Kortüm M, Knop S, Einsele H. Novel agents to improve outcome of allogeneic transplantation for patients with multiple myeloma. Future Oncology 2011;7:135-43. [DOI: 10.2217/fon.10.162] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
81 Noonan K, Rudraraju L, Ferguson A, Emerling A, Pasetti MF, Huff CA, Borrello I. Lenalidomide-induced immunomodulation in multiple myeloma: impact on vaccines and antitumor responses. Clin Cancer Res 2012;18:1426-34. [PMID: 22241792 DOI: 10.1158/1078-0432.CCR-11-1221] [Cited by in Crossref: 67] [Cited by in F6Publishing: 41] [Article Influence: 6.7] [Reference Citation Analysis]
82 Krieg S, Ullrich E. Novel immune modulators used in hematology: impact on NK cells. Front Immunol 2012;3:388. [PMID: 23316191 DOI: 10.3389/fimmu.2012.00388] [Cited by in Crossref: 22] [Cited by in F6Publishing: 32] [Article Influence: 2.4] [Reference Citation Analysis]
83 Lejeune FJ, Rimoldi D, Speiser D. New approaches in metastatic melanoma: biological and molecular targeted therapies. Expert Rev Anticancer Ther 2007;7:701-13. [PMID: 17492933 DOI: 10.1586/14737140.7.5.701] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 1.9] [Reference Citation Analysis]
84 Chan AC, Neeson P, Leeansyah E, Tainton K, Quach H, Prince HM, Godfrey DI, Ritchie D, Berzins SP. Testing the NKT cell hypothesis in lenalidomide-treated myelodysplastic syndrome patients. Leukemia 2010;24:592-600. [PMID: 20072154 DOI: 10.1038/leu.2009.279] [Cited by in Crossref: 24] [Cited by in F6Publishing: 26] [Article Influence: 2.0] [Reference Citation Analysis]
85 Khouri IF, Fernandez Curbelo I, Turturro F, Jabbour EJ, Milton DR, Bassett RL Jr, Vence LM, Allison JP, Gulbis AM, Sharma P. Ipilimumab plus Lenalidomide after Allogeneic and Autologous Stem Cell Transplantation for Patients with Lymphoid Malignancies. Clin Cancer Res 2018;24:1011-8. [PMID: 29246938 DOI: 10.1158/1078-0432.CCR-17-2777] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 4.4] [Reference Citation Analysis]
86 Ullenhag GJ, Mozaffari F, Broberg M, Mellstedt H, Liljefors M. Clinical and Immune Effects of Lenalidomide in Combination with Gemcitabine in Patients with Advanced Pancreatic Cancer. PLoS One 2017;12:e0169736. [PMID: 28099502 DOI: 10.1371/journal.pone.0169736] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
87 Cattrini C, Dellepiane C, Cavo A, Buzzatti G, Tolomeo F, Messina C, Boccardo F. Immunotherapy for genitourinary cancer: state of the art and new perspectives. Anti-Cancer Drugs 2016;27:585-99. [DOI: 10.1097/cad.0000000000000376] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
88 Segler A, Tsimberidou AM. Lenalidomide in solid tumors. Cancer Chemother Pharmacol. 2012;69:1393-1406. [PMID: 22584909 DOI: 10.1007/s00280-012-1874-2] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
89 Chan JK, Manuel MR, Ciaravino G, Cheung MK, Husain A, Teng NN. Safety and efficacy of thalidomide in recurrent epithelial ovarian and peritoneal carcinoma. Gynecol Oncol 2006;103:919-23. [PMID: 16828852 DOI: 10.1016/j.ygyno.2006.05.035] [Cited by in Crossref: 13] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
90 Sharma RA, Steward WP, Daines CA, Knight RD, O'Byrne KJ, Dalgleish AG. Toxicity profile of the immunomodulatory thalidomide analogue, lenalidomide: phase I clinical trial of three dosing schedules in patients with solid malignancies. Eur J Cancer 2006;42:2318-25. [PMID: 16899362 DOI: 10.1016/j.ejca.2006.05.018] [Cited by in Crossref: 43] [Cited by in F6Publishing: 42] [Article Influence: 2.7] [Reference Citation Analysis]
91 Melchert M, List A. The thalidomide saga. The International Journal of Biochemistry & Cell Biology 2007;39:1489-99. [DOI: 10.1016/j.biocel.2007.01.022] [Cited by in Crossref: 156] [Cited by in F6Publishing: 146] [Article Influence: 10.4] [Reference Citation Analysis]
92 Jin X, Lu S, Xing X, Wang L, Mu D, He M, Huang H, Zeng X, Chen Q. Thalidomide: features and potential significance in oral precancerous conditions and oral cancer. J Oral Pathol Med 2013;42:355-62. [DOI: 10.1111/jop.12004] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
93 Modena A, Massari F, Ciccarese C, Brunelli M, Santoni M, Montironi R, Martignoni G, Tortora G. Targeting Met and VEGFR Axis in Metastatic Castration-Resistant Prostate Cancer: ‘Game Over’? Targ Oncol 2016;11:431-46. [DOI: 10.1007/s11523-015-0412-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
94 Wryter LE, Solimando DA, Waddell JA. Deferasirox; Lenalidomide. Hosp Pharm 2006;41:420-5. [DOI: 10.1310/hpj4105-420] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
95 Eisen T, Trefzer U, Hamilton A, Hersey P, Millward M, Knight RD, Jungnelius JU, Glaspy J. Results of a multicenter, randomized, double-blind phase 2/3 study of lenalidomide in the treatment of pretreated relapsed or refractory metastatic malignant melanoma. Cancer 2010;116:146-54. [PMID: 19862820 DOI: 10.1002/cncr.24686] [Cited by in Crossref: 3] [Cited by in F6Publishing: 14] [Article Influence: 0.3] [Reference Citation Analysis]
96 Kalmadi S, Davis M, Dowlati A, O’keefe S, Cline-burkhardt M, Pelley RJ, Borden E, Dreicer R, Bukowski R, Mekhail T. Phase I trial of three-weekly Docetaxel, Carboplatin and oral lenalidomide (Revlimid®) in patients with advanced solid tumors. Invest New Drugs 2007;25:211-6. [DOI: 10.1007/s10637-006-9025-4] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
97 Dalgleish A, Galustian C. The potential of immunomodulatory drugs in the treatment of solid tumors. Future Oncol 2010;6:1479-84. [PMID: 20919830 DOI: 10.2217/fon.10.105] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
98 Dalgleish AG. Rationale for combining immunotherapy with chemotherapy. Immunotherapy 2015;7:309-16. [DOI: 10.2217/imt.14.111] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 4.1] [Reference Citation Analysis]
99 Semeraro M, Vacchelli E, Eggermont A, Galon J, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Lenalidomide-based immunochemotherapy. Oncoimmunology 2013;2:e26494. [PMID: 24482747 DOI: 10.4161/onci.26494] [Cited by in Crossref: 39] [Cited by in F6Publishing: 39] [Article Influence: 4.3] [Reference Citation Analysis]
100 Gullestad L, Kjekshus J, Damås JK, Ueland T, Yndestad A, Aukrust P. Agents targeting inflammation in heart failure. Expert Opinion on Investigational Drugs 2005;14:557-66. [DOI: 10.1517/13543784.14.5.557] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 1.1] [Reference Citation Analysis]
101 Dulphy N, Chrétien AS, Khaznadar Z, Fauriat C, Nanbakhsh A, Caignard A, Chouaib S, Olive D, Toubert A. Underground Adaptation to a Hostile Environment: Acute Myeloid Leukemia vs. Natural Killer Cells. Front Immunol 2016;7:94. [PMID: 27014273 DOI: 10.3389/fimmu.2016.00094] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
102 Glaspy J, Atkins MB, Richards JM, Agarwala SS, O'Day S, Knight RD, Jungnelius JU, Bedikian AY. Results of a multicenter, randomized, double-blind, dose-evaluating phase 2/3 study of lenalidomide in the treatment of metastatic malignant melanoma. Cancer 2009;115:5228-36. [PMID: 19728370 DOI: 10.1002/cncr.24576] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
103 Dimopoulos MA, Hussein M, Swern AS, Weber D. Impact of lenalidomide dose on progression-free survival in patients with relapsed or refractory multiple myeloma. Leukemia 2011;25:1620-6. [PMID: 21747400 DOI: 10.1038/leu.2011.126] [Cited by in Crossref: 14] [Cited by in F6Publishing: 18] [Article Influence: 1.3] [Reference Citation Analysis]
104 Cortés-Hernández J, Ávila G, Vilardell-Tarrés M, Ordi-Ros J. Efficacy and safety of lenalidomide for refractory cutaneous lupus erythematosus. Arthritis Res Ther 2012;14:R265. [PMID: 23217273 DOI: 10.1186/ar4111] [Cited by in Crossref: 42] [Cited by in F6Publishing: 35] [Article Influence: 4.2] [Reference Citation Analysis]
105 Jung YJ, Tweedie D, Scerba MT, Greig NH. Neuroinflammation as a Factor of Neurodegenerative Disease: Thalidomide Analogs as Treatments. Front Cell Dev Biol 2019;7:313. [PMID: 31867326 DOI: 10.3389/fcell.2019.00313] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 11.0] [Reference Citation Analysis]
106 Bamias A, Dimopoulos MA. Thalidomide and immunomodulatory drugs in the treatment of cancer. Expert Opinion on Investigational Drugs 2005;14:45-55. [DOI: 10.1517/13543784.14.1.45] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]